Clinical Trial

Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 21, 2024 (before its estimated July 2025 completion). Its status may not reflect the trial's current state.
Summary
Cadonilimab, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy. The aim of this study is to evaluate the efficacy and safety of cadonilimab in combination with bevacizumab and standard chemotherapy as first Line therapy in unresectable pleural mesothelioma.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT05930665
Lead Sponsor Sun Yat-sen University
Conditions Pleural Mesothelioma
Enrollment 38 participants
Start Date 2023-11-01
Primary Completion 2025-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2024-02-21